rivastigmine has been researched along with Down Syndrome in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, JA; Capone, GT; Hart, SJ; Heller, JH; Kishnani, PS; Schneider, HE; Spiridigliozzi, GA; Weadon, C | 1 |
| Bennett, C; Carpenter, PK; Mohan, M | 1 |
| Crissman, BG; Heller, JH; Kishnani, PS; McKillop, JA; Spiridigliozzi, GA; Yamamoto, H | 1 |
| Adams, C; Haque, MS; Prasher, VP; Sachdeva, N | 1 |
| Prasher, VP | 1 |
| Adams, C; Fung, N; Prasher, VP | 1 |
| Crissman, BG; Doraiswamy, PM; Eells, RL; Heller, JH; Kishnani, PS; Krishnan, KR; Li, JS; Spiridigliozzi, GA; Sullivan, JA | 1 |
| Lee, MR; Padua, Y; Stevens, DL | 1 |
2 review(s) available for rivastigmine and Down Syndrome
| Article | Year |
|---|---|
Rivastigmine for dementia in people with Down syndrome.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Down Syndrome; Humans; Phenylcarbamates; Rivastigmine | 2009 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2004 |
3 trial(s) available for rivastigmine and Down Syndrome
| Article | Year |
|---|---|
Safety and efficacy of rivastigmine in children with Down syndrome: A double blind placebo controlled trial.
Topics: Adaptation, Psychological; Adolescent; Child; Cognition; Down Syndrome; Electrocardiography; Female; Humans; Male; Rivastigmine; Treatment Outcome | 2016 |
Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up.
Topics: Adolescent; Cognition; Down Syndrome; Follow-Up Studies; Humans; Language Disorders; Language Tests; Male; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Time Factors | 2010 |
Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Down Syndrome; Female; Humans; Male; Middle Aged; Nootropic Agents; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2005 |
3 other study(ies) available for rivastigmine and Down Syndrome
| Article | Year |
|---|---|
Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study.
Topics: Alzheimer Disease; Analysis of Variance; Delayed-Action Preparations; Down Syndrome; Female; Humans; Male; Medication Adherence; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Pilot Projects; Rivastigmine; Transdermal Patch | 2013 |
Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
Topics: Adaptation, Psychological; Adolescent; Attention; Child; Cholinesterase Inhibitors; Down Syndrome; Female; Humans; Language; Male; Memory; Patient Compliance; Phenylcarbamates; Rivastigmine; Verbal Behavior | 2006 |
Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.
Topics: Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Dementia; Down Syndrome; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Phenylcarbamates; Rivastigmine | 2008 |